How Does SUS Integrity Change Across Drug Product Lifecycle?

Single-use systems must protect the sterile pathway and perform as intended throughout use. Yet the evidence needed to demonstrate integrity changes as a drug program advances. Early development may rely on risk-based justification, while commercialization and post-approval stages require stronger validation, documentation, and lifecycle controls. Applying the same strategy at every phase can create gaps between existing practices and regulatory expectations, leading to rework, delays, or inspection challenges. A phase-appropriate approach connects system selection, risk assessment, validation planning, and ongoing control to the maturity of the program.

Explore regulatory services and supporting documentation that can help drug product manufacturers build that alignment earlier, strengthen sterility assurance, and improve contamination control.